Pediatric Patients Aged 4 to 11 Years With APDS

Key facts

Sponsor

Pharming Technologies B.V.

Intervention

Leniolisib(drug)

Enrollment

15 enrolled

Eligibility

4-11 years · All sexes

Timeline

2023 – 2025

Study locations (7)

• University of California Los Angeles, Los Angeles, California, United States
• Stanford University, Standford, California, United States
• Children's Healthcare of Atlanta, Atlanta, Georgia, United States
• National Institutes of Health, Bethesda, Maryland, United States
• Necker Hospital Paris, Paris, France
• Kyoto University Hospital, Kyoto, Japan
• Institute of Science Tokyo Hospital, Tokyo, Japan

Collaborators

CMIC Co, Ltd. Japan · Labcorp Central Laboratory · Fortrea · Aixial Group

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Activated PI3K-delta syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06694363
  New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome
  Assistance Publique - Hôpitaux de Paris
• ACTIVE NOT RECRUITINGPHASE3NCT05693129
  Pediatric Patients Aged 1 to 6 Years With APDS
  Pharming Technologies B.V.
• RECRUITINGNCT06566872
  Collecting Recorded Videos of Colonoscopy and Gastroscopy Tests for the Evaluation of the (ME-APDS).
  Magentiq Eye LTD

See all trials for Activated PI3K-delta syndrome →